Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

As more doctors and patients turn to the latest weight-loss drugs, researchers are trying to figure out which drug is right ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...